Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Penicillins	O
/	O
Sulfa	O
(Sulfonamide	O
Antibiotics)	O
/	O
dapsone	O
Attending:	O
___	O
___	O
Complaint:	O
worsening	O
back	O
pain	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
none	O
History	O
of	O
Present	O
Illness:	O
Ms.	O
___	O
is	O
a	O
___	O
y/o	O
female	O
dx	O
with	O
IgA	O
lambda	O
Multiple	O
myeloma	O
originally	O
dx	O
in	O
___.	O
She	O
is	O
s/p	O
multiple	O
treatments	O
in	O
the	O
past	O
most	O
recently	O
s/p	O
cycle	O
1	O
of	O
velcade/dex	O
administered	O
weekly	O
as	O
of	O
___.	O
She	O
was	O
admitted	O
from	O
clinic	O
due	O
to	O
worsening	O
back	O
pain.	O
She	O
has	O
a	O
history	O
of	O
spinal	O
stenosis	O
involving	O
L4-L5,	O
T12	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fx,	B-Vertebral_compression_fracture
and	O
osteopenia.	O
She	O
does	O
not	O
have	O
a	O
history	O
of	O
lytic	O
lesions.	O
She	O
presents	O
with	O
worsening	O
back	O
pain	O
over	O
the	O
last	O
weekend	O
and	O
concern	O
for	O
myeloma	O
reoccurance.	O
Past	O
Medical	O
History:	O
*	O
Status	O
post	O
2-CdA	O
therapy	O
with	O
Cytoxan	O
and	O
Rituxan	O
in	O
___	O
and	O
___.	O
*	O
Status	O
post	O
six	O
cycles	O
of	O
Velcade	O
completing	O
on	O
___.	O
*	O
Brief	O
trial	O
of	O
thalidomide	O
starting	O
at	O
the	O
end	O
of	O
___	O
and	O
increasing	O
doses	O
to	O
100	O
mg	O
with	O
poor	O
tolerance	O
due	O
to	O
complaints	O
of	O
lightheadedness	O
and	O
fatigue.	O
Thalidomide	O
discontinued	O
in	O
___,	O
restarted	O
thalidomide	O
on	O
___	O
and	O
continued	O
this	O
until	O
___	O
at	O
a	O
lower	O
dose.	O
*	O
Enrolment	O
on	O
the	O
dendritic	O
cell/tumor	O
vaccine	O
study	O
___	O
with	O
successful	O
generation	O
of	O
vaccine.	O
Received	O
a	O
total	O
of	O
four	O
vaccines	O
with	O
her	O
last	O
vaccine	O
on	O
___	O
with	O
evidence	O
of	O
disease	O
progression	O
approximately	O
five	O
months	O
after	O
her	O
vaccine	O
therapy.	O
*	O
Started	O
pulse	O
Decadron	O
therapy	O
at	O
20	O
mg	O
daily	O
for	O
six	O
days	O
on	O
___.	O
*	O
Restarted	O
Decadron	O
at	O
20	O
mg	O
daily	O
for	O
two	O
days	O
per	O
week	O
for	O
three-week	O
cycle,	O
then	O
in	O
___	O
began	O
on	O
two	O
days	O
of	O
Decadron	O
every	O
other	O
week,	O
which	O
was	O
discontinued	O
at	O
the	O
end	O
of	O
___	O
with	O
an	O
excellent	O
response	O
to	O
therapy.	O
*	O
Noted	O
for	O
increase	O
in	O
IgA	O
and	O
completed	O
two	O
pulses	O
of	O
Decadron	O
20	O
mg	O
daily	O
for	O
two	O
days	O
taken	O
weekly	O
for	O
three	O
weeks	O
with	O
first	O
pulse	O
on	O
___	O
and	O
second	O
pulse	O
on	O
___.	O
*	O
Another	O
pulse	O
of	O
Decadron	O
20	O
mg	O
daily	O
for	O
two	O
days	O
for	O
three	O
weeks,	O
started	O
on	O
___.	O
*	O
Pulse	O
of	O
Decadron	O
20	O
mg	O
daily	O
for	O
2	O
days/week	O
for	O
3	O
weeks	O
starting	O
___.	O
*	O
Trial	O
of	O
Curcumin,	O
1000	O
mg	O
twice	O
per	O
day(2	O
tablets	O
twice	O
per	O
day).	O
Stopped	O
in	O
___	O
due	O
to	O
side	O
effects.	O
*	O
Decadron	O
pulse	O
starting	O
on	O
___:	O
2	O
days	O
of	O
20	O
mg,	O
followed	O
by	O
2	O
days	O
of	O
4	O
mg;	O
repeated	O
the	O
following	O
week.	O
*	O
Decadron	O
pulse	O
in	O
mid	O
___	O
with	O
20	O
mg	O
daily	O
for	O
3	O
days	O
prior	O
to	O
aortic	O
valve	O
replacement	O
on	O
___.	O
*	O
Decadron	O
pulse	O
in	O
mid	O
___	O
with	O
10	O
mg	O
for	O
2	O
days	O
followed	O
by	O
2	O
days	O
of	O
4	O
mg	O
and	O
repeated	O
in	O
1	O
week.	O
*	O
Decadron	O
pulse	O
in	O
late	O
___	O
with	O
12	O
mg	O
for	O
4	O
days,	O
hold	O
for	O
5	O
days	O
and	O
then	O
repeat	O
Decadron	O
12	O
mg	O
for	O
4	O
days.	O
*	O
Increasing	O
shortness	O
of	O
breath	O
with	O
repeat	O
echocardiogram	O
and	O
evaluation	O
by	O
cardiologist.	O
No	O
issues	O
regarding	O
her	O
aortic	O
valve.	O
Diltiazem	O
dose	O
decreased	O
as	O
her	O
blood	O
pressure	O
was	O
lower.	O
Received	O
unit	O
of	O
red	O
cells	O
on	O
___	O
for	O
Hct	O
~	O
30%with	O
no	O
significant	O
change	O
in	O
her	O
symptoms.	O
CT	O
scan	O
of	O
the	O
chest	O
showed	O
some	O
small	O
nodules	O
but	O
felt	O
not	O
enough	O
to	O
contribute	O
to	O
her	O
dyspnea.	O
Etiology	O
felt	O
related	O
to	O
deconditioning	O
with	O
decreased	O
activity.	O
*	O
Increasing	O
lower	O
back	O
pain	O
radiating	O
down	O
her	O
left	O
leg.	O
Has	O
severe	O
spinal	O
stenosis;	O
underwent	O
steroid	O
epidural	O
injection	O
at	O
L3-4	O
on	O
___	O
with	O
marked	O
improvement	O
in	O
her	O
pain.	O
*	O
Slowly	O
increasing	O
IgA	O
level	O
and	O
took	O
another	O
Decadron	O
pulse	O
in	O
___	O
of	O
20	O
mg	O
daily	O
for	O
3	O
days,	O
then	O
8	O
mg	O
for	O
2	O
days,	O
then	O
4	O
mg	O
for	O
2	O
days.	O
*	O
Slowly	O
increasing	O
IgA	O
level	O
and	O
took	O
another	O
Decadron	O
pulse	O
in	O
___	O
of	O
20	O
mg	O
daily	O
for	O
4	O
days,	O
then	O
8	O
mg	O
for	O
2	O
days,	O
then	O
4	O
mg	O
for	O
2	O
days.	O
*	O
Increasing	O
IgA	O
once	O
again	O
and	O
received	O
Decadron	O
pulse	O
of	O
20	O
mg	O
for	O
2	O
days,	O
followed	O
by	O
8	O
mg	O
for	O
2	O
days	O
and	O
4	O
mg	O
for	O
2	O
days,	O
then	O
1	O
cycle	O
of	O
Velcade	O
1	O
mg/m2	O
SQ	O
and	O
Decadron	O
on	O
day	O
of	O
Velcade	O
for	O
3	O
weeks	O
in	O
___.	O
*	O
IgA	O
slightly	O
increased	O
but	O
more	O
noted	O
increasing	O
BJP	O
excretion	O
of	O
3200	O
mg/day	O
as	O
of	O
___.	O
Given	O
Decadron	O
pulse	O
20	O
mg	O
2	O
days,	O
then	O
8	O
mg	O
for	O
2	O
days,	O
then	O
4	O
mg	O
for	O
2	O
days	O
as	O
of	O
___	O
and	O
then	O
on	O
___,	O
initiated	O
another	O
cycle	O
of	O
Velcade	O
~	O
1	O
mg/m2	O
on	O
D	O
1,	O
8,	O
15	O
with	O
Decadron	O
on	O
day	O
of	O
treatment.	O
*	O
___,	O
noted	O
for	O
increasing	O
creatinine	O
to	O
2.3	O
with	O
increased	O
free	O
light	O
chain	O
ratio	O
and	O
increased	O
BJP	O
excretion.	O
Started	O
on	O
Velcade	O
@	O
1	O
mg/m2	O
and	O
Decadron	O
with	O
3	O
weeks	O
on,	O
1	O
week	O
of	O
with	O
additional	O
short	O
pulse	O
of	O
Decadron	O
12	O
mg	O
for	O
4	O
days	O
starting	O
on	O
D	O
1.	O
*	O
___,	O
Velcade	O
@	O
1	O
mg/m2	O
with	O
Decadron	O
10	O
mg	O
weekly	O
x	O
3	O
weeks.	O
*	O
___,	O
presents	O
for	O
next	O
cycle.	O
*	O
___,	O
Velcade	O
@	O
1.3	O
mg/m2	O
with	O
Decadron	O
10	O
mg	O
weekly	O
x	O
3	O
weeks.	O
*	O
___,	O
10	O
g	O
IVIG	O
*	O
Persistent	O
cough	O
and	O
admitted	O
on	O
___	O
with	O
cough	O
with	O
hypoxia.	O
Noncontrast	O
chest	O
CT	O
was	O
negative	O
for	O
pulmonary	O
infiltrate	O
or	O
sign	O
of	O
fluid	O
overload.	O
Lung	O
scan	O
was	O
consistent	O
with	O
low	O
probability	O
of	O
pulmonary	O
embolism.	O
Discharged	O
with	O
home	O
oxygen	O
which	O
she	O
uses	O
as	O
needed	O
with	O
improvement	O
over	O
time.	O
*	O
Increasing	O
IgA	O
and	O
FLC	O
assay.	O
Treatment	O
schedule	O
switched	O
to	O
Velcade	O
D	O
1,4,8	O
and	O
11	O
with	O
Decadron	O
on	O
day	O
of	O
and	O
day	O
after	O
Velcade.	O
D1	O
given	O
on	O
___.	O
D	O
8	O
held	O
due	O
to	O
noted	O
hemolysis	O
felt	O
related	O
to	O
Decadron.	O
*	O
___	O
Velcade	O
D	O
1,4,8	O
and	O
11	O
with	O
Decadron	O
on	O
day	O
of	O
and	O
day	O
after	O
Velcade.	O
D	O
11	O
held	O
with	O
increased	O
dyspnea.	O
*	O
___	O
Admitted	O
with	O
unstable	O
angina,	O
CHF	O
and	O
cardionyopathy.	O
Medications	O
adjusted.	O
*	O
___	O
switched	O
to	O
velcade/dex	O
day	O
1	O
and	O
4	O
every	O
other	O
week	O
PAST	O
MEDICAL/SURGICAL	O
HISTORY	O
(per	O
NP	O
___	O
___	O
note,	O
confirmed	O
with	O
patient):	O
1.	O
Severe	O
abdominal	O
pain	O
in	O
___	O
requiring	O
admission;	O
CT	O
scan	O
showed	O
ischemic	O
colitis	O
of	O
transverse	O
colon	O
at	O
splenic	O
flexure.	O
Treated	O
with	O
bowel	O
rest	O
and	O
antibiotics.	O
Discharged	O
on	O
___	O
with	O
improved	O
symptoms.	O
Repeat	O
colonoscopy	O
on	O
___	O
showed	O
ischemic	O
colitis.	O
2.	O
CAD	O
status	O
post	O
CABG	O
x	O
2	O
in	O
___	O
and	O
___.	O
3.	O
Critical	O
aortic	O
stenosis	O
with	O
aortic	O
valve	O
replacement	O
on	O
___.	O
Experimental	O
surgical	O
technique	O
used	O
approach	O
through	O
the	O
left	O
lateral	O
chest	O
wall.	O
4.	O
Multiple	O
myeloma	O
as	O
above.	O
5.	O
Hypertension;	O
Hyperlipidemia	O
6.	O
Zoster	O
7.	O
Paroxysmal	O
atrial	O
fibrillation	O
8.	O
Hypothyroidism	O
Social	O
History:	O
___	O
Family	O
History:	O
Her	O
father	O
died	O
of	O
MI.	O
Mother	O
died	O
of	O
EtOH	O
cirrhosis.	O
No	O
known	O
h/o	O
clots.	O
Physical	O
Exam:	O
PHYSICAL	O
EXAM:	O
GEN:	O
WDWN	O
NAD	O
A&Ox4	B-Delirium
HEENT:	O
oropharynx	O
moist.	O
CV:	O
irreg	O
irreg	O
no	O
m/r/g	O
PULM:	O
CTA	O
ABD:	O
soft	O
protuberant	O
+BS	O
NT	O
EXTR:	O
No	O
edema,	O
no	O
inguinal	O
adenopathy	O
SKIN:	O
No	O
rashes	O
or	O
skin	O
breakdown	O
NEURO:	O
Grossly	O
nonfocal,	O
alert	O
and	O
oriented	B-Delirium
No	O
paraspinous	O
tenderness	O
Pertinent	O
Results:	O
___	O
01:05PM	O
___	O
___	O
___	O
01:05PM	O
PLT	O
COUNT-212	O
___	O
01:05PM	O
NEUTS-81.7*	O
LYMPHS-11.8*	O
MONOS-5.9	O
EOS-0.6	O
BASOS-0.2	O
___	O
01:05PM	O
WBC-14.4*	O
RBC-3.78*	O
HGB-11.7*	O
HCT-35.7*	O
MCV-94	O
MCH-30.8	O
MCHC-32.7	O
RDW-15.7*	O
___	O
01:05PM	O
URINE	O
U-PEP-ABNORMAL	O
B	O
___	O
01:05PM	O
URINE	O
HOURS-RANDOM	O
CREAT-68	O
TOT	O
PROT-99	O
PROT/CREA-1.5*	O
___	O
01:05PM	O
Free	O
K-12.5	O
Free	O
L-201.1*	O
Fr	O
K/L-0.06*	O
IgG-343*	O
IgA-31*	O
IgM-27*	O
___	O
01:05PM	O
TSH-5.2*	O
___	O
01:05PM	O
TOT	O
PROT-5.9*	O
ALBUMIN-4.3	O
GLOBULIN-1.6*	O
CALCIUM-10.0	O
MAGNESIUM-2.0	O
___	O
01:05PM	O
ALT(SGPT)-23	O
AST(SGOT)-28	O
LD(LDH)-313*	O
ALK	O
PHOS-76	O
TOT	O
BILI-0.5	O
___	O
01:05PM	O
UREA	O
N-24*	O
CREAT-1.0	O
SODIUM-140	O
POTASSIUM-5.1	O
CHLORIDE-100	O
TOTAL	O
CO2-29	O
ANION	O
GAP-___	O
year	O
old	O
female	O
with	O
IgA	O
lambda	O
mulitple	O
myeloma	O
most	O
recently	O
s/p	O
C1	O
of	O
vel/dex	O
weekly.	O
She	O
was	O
admitted	O
from	O
clinic	O
on	O
___	O
secondary	O
to	O
acute	O
on	O
chronic	O
back	O
pain.	O
#	O
Multiple	O
Myeloma:	O
The	O
patient	O
initiated	O
vel/dex	O
weekly	O
as	O
palliation	O
treatment	O
as	O
of	O
___.	O
She	O
was	O
due	O
to	O
initiate	O
cycle	O
2	O
on	O
___	O
consisting	O
of	O
SQ	O
velcade	O
and	O
dexamethasone	O
the	O
day	O
on	O
and	O
after	O
velcade.	O
This	O
is	O
currently	O
held	O
until	O
post	O
kypoplasty	O
procedure.	O
She	O
will	O
follow	O
up	O
with	O
hematology	O
on	O
___	O
for	O
further	O
discussion	O
of	O
treatment.	O
#Compression	I-Vertebral_compression_fracture
fx	B-Vertebral_compression_fracture
and	O
spinal	B-Vertebral_compression_fracture
stenosis.	O
The	O
patient	O
has	O
a	O
history	O
of	O
chronic	O
back	O
pain	O
secondary	O
to	O
spinal	B-Vertebral_compression_fracture
stenosis,	O
compression	B-Vertebral_compression_fracture
fx	B-Vertebral_compression_fracture
s/p	O
kyphoplasty,	O
and	O
osteopenia.	O
The	O
patient	O
does	O
not	O
have	O
a	O
history	O
of	O
lytic	O
lesions	O
associated	O
with	O
her	O
myeloma.	O
Patient	O
MRI	O
of	O
thoracic/lumbar	O
spine	O
___	O
consistnet	O
with	O
new	O
T10	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fx.	B-Vertebral_compression_fracture
To	O
undergo	O
kypoplasty	O
with	O
Dr.	O
___	O
spine	O
physician,	O
as	O
an	O
outpatient.	O
F/u	O
with	O
Dr	O
___	O
has	O
been	O
arranged	O
for	O
___.	O
On	O
vit	O
D.	O
#	O
Pain	O
control.	O
Secondary	O
to	O
chronic	O
back	O
pain	O
as	O
stated	O
above.	O
Will	O
continue	O
tylenol	O
prn.	O
Pain	O
medications	O
at	O
home	O
include	O
dilaudid	O
prn,	O
vicodin	O
prn,	O
and	O
gabapentin.	O
She	O
does	O
not	O
like	O
narcotics	O
or	O
her	O
gabapentin	O
as	O
it	O
makes	O
her	O
drowsy.	O
She	O
has	O
not	O
been	O
taking	O
gabapentin	O
or	O
vicodin.	O
She	O
has	O
been	O
seen	O
by	O
Dr.	O
___	O
in	O
regards	O
to	O
pain	O
management	O
and	O
spine.	O
She	O
last	O
received	O
a	O
steriod	O
injection	O
___	O
which	O
alleviated	O
her	O
lumbar	O
radiculopathy.	O
She	O
will	O
continue	O
lidoderm	O
patch	O
for	O
relief.	O
Pain	O
service	O
continues	O
to	O
follow	O
up.	O
She	O
will	O
use	O
the	O
dilaudid	O
po	O
at	O
home.	O
The	O
4mg	O
dose	O
seems	O
to	O
help	O
prior	O
to	O
activity.	O
This	O
has	O
been	O
discussed	O
with	O
the	O
patient.	O
She	O
will	O
remain	O
on	O
her	O
home	O
bowel	O
regimen	O
of	O
colace,	O
senna,	O
and	O
prunes.	O
#	O
esophageal	O
dilation:	O
seen	O
incidentally	O
on	O
MRI.	O
was	O
present	O
at	O
least	O
since	O
___	O
per	O
radiology.	O
minimal	O
sx,	O
of	O
a	O
recent	O
duration.	O
would	O
defer	O
this	O
workup,	O
if	O
needed,	O
until	O
after	O
acute	O
issues	O
have	O
been	O
dealt	O
with.	O
#Cardio.	O
Patient	O
has	O
an	O
extensive	O
cardiac	O
history	O
including	O
CAD	O
s/p	O
2	O
bypass	O
surgeries,	O
aortic	O
stenosis,	O
s/p	O
valve	O
replacement,	O
CHF,	O
and	O
paroxysmal	O
a	O
fib.	O
She	O
is	O
seen	O
regularly	O
by	O
her	O
cardiologist	O
Dr.	O
___	O
follow	O
ups.	O
1	O
unit	O
of	O
pRBC's	O
was	O
given	O
on	O
___	O
for	O
her	O
known	O
coronary	O
disease	O
in	O
the	O
setting	O
of	O
anemia.	O
#	O
Renal	O
insufficiency.	O
Secondary	O
to	O
multiple	O
myeloma.	O
Remained	O
stable.	O
Cr	O
baseline	O
1.0-1.4.	O
#	O
Infectious	O
prophylaxis:	O
-	O
PCP:	O
pentamidine	O
monthly,	O
received	O
in-house	O
on	O
___	O
prior	O
to	O
discharge.	O
-	O
HSV/VZV:	O
acyclovir	O
Prophylaxes:	O
#	O
Access:	O
peripheral	O
#	O
FEN:	O
Regular	O
diet	O
#	O
Bowel	O
regimen:	O
colace,	O
senna	O
prn	O
#	O
Contact:	O
___	O
#	O
Disposition:	O
home	O
today	O
with	O
sister.	O
___	O
evaluated,	O
no	O
recomendation	O
for	O
services.	O
#	O
Code	O
status:	O
full	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Acyclovir	O
400	O
mg	O
PO	O
Q12H	O
2.	O
ALPRAZolam	O
0.5-1	O
mg	O
PO	O
ONCE	O
pre	O
MRI	O
3.	O
Atorvastatin	O
80	O
mg	O
PO	O
DAILY	O
4.	O
ClonazePAM	O
0.5-1	O
mg	O
PO	O
QHS:PRN	O
insomnia	O
5.	O
Digoxin	O
0.125	O
mg	O
PO	O
QMOWEFR	O
6.	O
Diltiazem	O
Extended-Release	O
120	O
mg	O
PO	O
Q12H	O
7.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
8.	O
HYDROmorphone	O
(Dilaudid)	O
2	O
mg	O
PO	O
Q4H:PRN	O
pain	O
9.	O
Levothyroxine	O
Sodium	O
100	O
mcg	O
PO	O
DAILY	O
10.	O
Hydrocodone-Acetaminophen	O
(5mg-500mg)	O
___	O
TAB	O
PO	O
Q6H:PRN	O
pain	O
11.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
PO	O
BID	O
12.	O
Pentamidine-Inhalation	O
300	O
mg	O
IH	O
ONCE	O
13.	O
Lidocaine	O
5%	O
Patch	O
1	O
PTCH	O
TD	O
QAM	O
14.	O
Aspirin	O
325	O
mg	O
PO	O
DAILY	O
15.	O
Nephrocaps	O
1	O
CAP	O
PO	O
DAILY	O
16.	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
17.	O
Cyanocobalamin	O
500	O
mcg	O
PO	O
DAILY	O
18.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID:PRN	O
constipation	B-Constipation
19.	O
Fish	O
Oil	O
(Omega	O
3)	O
1000	O
mg	O
PO	O
DAILY	O
20.	O
Pyridoxine	O
50	O
mg	O
PO	O
DAILY	O
21.	O
Senna	O
1	O
TAB	O
PO	O
BID:PRN	O
constipation	B-Constipation
Discharge	O
Medications:	O
1.	O
Acyclovir	O
400	O
mg	O
PO	O
Q12H	O
2.	O
Aspirin	O
325	O
mg	O
PO	O
DAILY	O
3.	O
Atorvastatin	O
80	O
mg	O
PO	O
DAILY	O
4.	O
ClonazePAM	O
0.5-1	O
mg	O
PO	O
QHS:PRN	O
insomnia	O
5.	O
Cyanocobalamin	O
500	O
mcg	O
PO	O
DAILY	O
6.	O
Digoxin	O
0.125	O
mg	O
PO	O
QMOWEFR	O
7.	O
Diltiazem	O
Extended-Release	O
120	O
mg	O
PO	O
Q12H	O
8.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID:PRN	O
constipation	B-Constipation
9.	O
Fish	O
Oil	O
(Omega	O
3)	O
1000	O
mg	O
PO	O
DAILY	O
10.	O
Furosemide	O
20	O
mg	O
PO	O
DAILY	O
11.	O
Levothyroxine	O
Sodium	O
100	O
mcg	O
PO	O
DAILY	O
12.	O
Lidocaine	O
5%	O
Patch	O
1	O
PTCH	O
TD	O
QAM	O
13.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
PO	O
BID	O
14.	O
Nephrocaps	O
1	O
CAP	O
PO	O
DAILY	O
15.	O
Pentamidine-Inhalation	O
300	O
mg	O
IH	O
ONCE	O
Duration:	O
1	O
Dose	O
FOR	O
INHALATION	O
ONLY	O
*Admin/Prep	O
Precautions*	O
16.	O
Pyridoxine	O
50	O
mg	O
PO	O
DAILY	O
17.	O
Senna	O
1	O
TAB	O
PO	O
BID:PRN	O
constipation	B-Constipation
18.	O
Vitamin	O
D	O
1000	O
UNIT	O
PO	O
DAILY	O
19.	O
Acetaminophen	O
325-650	O
mg	O
PO	O
Q6H:PRN	O
pain	O
20.	O
HYDROmorphone	O
(Dilaudid)	O
___	O
mg	O
PO	O
Q4H:PRN	O
pain	O
RX	O
*hydromorphone	O
2	O
mg	O
___	O
tablet(s)	O
by	O
mouth	O
every	O
four	O
(4)	O
hours	O
Disp	O
#*90	O
Tablet	O
Refills:*0	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
primary	O
t10	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fracture	B-Vertebral_compression_fracture
myeloma	O
anemia	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection	B-Urinary_tract_infection
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
to	O
the	O
hospital	O
to	O
help	O
control	O
a	O
sudden	O
worsening	O
of	O
your	O
chronic	O
back	O
pain	O
and	O
to	O
make	O
sure	O
you	O
did	O
not	O
have	O
a	O
compression	O
of	O
your	O
spinal	O
cord.	O
You	O
had	O
an	O
MRI	O
which	O
showed	O
no	O
spinal	O
cord	O
compression	O
but	O
did	O
show	O
a	O
possible	O
new	O
vertebral	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fracture	B-Vertebral_compression_fracture
at	O
T10.	B-Vertebral_compression_fracture
Your	O
pain	O
was	O
controlled	O
initially	O
with	O
IV	O
Dilaudid	O
which	O
was	O
then	O
switched	O
to	O
a	O
Dilaudid	O
pill.	O
If	O
your	O
pain	O
is	O
well	O
controlled,	O
you	O
do	O
not	O
need	O
any	O
further	O
intervention	O
for	O
your	O
vertebral	B-Vertebral_compression_fracture
compression	B-Vertebral_compression_fracture
fracture	B-Vertebral_compression_fracture
at	O
this	O
time.	O
Followup	O
Instructions:	O
___	O

